Asenapine alters the activity of monoaminergic systems following its subacute and long-term administration: An in vivo electrophysiological characterization

European Neuropsychopharmacology

Volumn 25, Issue 4, 2015, Pages 531-543

  Oosterhof, Chris A ^a   El Mansari, Mostafa ^a   Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Asenapine; Dopamine; Electrophysiology; Norepinephrine; Serotonin

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; APOMORPHINE; ASENAPINE; DOPAMINE 2 RECEPTOR; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; BIOGENIC AMINE; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT; SEROTONIN RECEPTOR AFFECTING AGENT;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; ELECTROSTIMULATION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; IONTOPHORESIS; LOCUS CERULEUS; MALE; MONOAMINERGIC SYSTEM; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC NERVE CELL; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SENSITIZATION; SEROTONIN BLOOD LEVEL; SEROTONINERGIC SYSTEM; VENTRAL TEGMENTUM; ANIMAL; BRAIN; CLASSIFICATION; CYTOLOGY; DRUG EFFECTS; METABOLISM; NERVE CELL; SPRAGUE DAWLEY RAT; TIME FACTOR;

ACTION POTENTIALS; ANIMALS; ANTIPSYCHOTIC AGENTS; BIOGENIC MONOAMINES; BRAIN; ELECTRIC STIMULATION; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; MALE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN AGENTS; TIME FACTORS;

EID: 84928215319     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.01.006     Document Type: Article

References (48)

1. Bang-Andersen B., Ruhland T., Jørgensen M., Smith G., Frederiksen K., Jensen K.G., Stensbøl T.B. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J.Med. Chem. 2011, 54(9):3206-3221.
2. Blackburn T.P., Suzuki K., Ashby C.R. The acute and chronic administration of the 5-HT(2B/2C) receptor antagonist SB-200646A significantly alters the activity of spontaneously active midbrain dopamine neurons in the rat: an in vivo extracellular single cell study. Synapse 2006, 59(8):502-512.
3. Blier P., Ramdine R., Galzin A.M., Langer S.Z. Frequency-dependence of serotonin autoreceptor but not alpha 2-adrenoceptor inhibition of [3H]-serotonin release in rat hypothalamic slices. Arch. Pharmacol. 1989, 339(1-2):60-64.
4. Blier P., Szabo S.T. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J. Clin. Psychiatry 2005, 66(Suppl. 8):S30-S40.
5. Buchanan R.W., Panagides J., Zhao J., Phiri P., den Hollander W., Ha X., Cazorla P. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J. Clin. Psychopharmacol. 2012, 32(1):36-45.
6. Chapel S., Hutmacher M.M., Haig G., Bockbrader H., de Greef R., Preskorn S.H., Lalonde R.L. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J. Clin. Pharmacol. 2009, 49(11):1297-1308.
7. Chaput Y., Blier P., de Montigny C. In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals. J. Neurosci. 1986, 6(10):2796-2801.
8. Chenu F., El Mansari M., Blier P. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology 2013, 38(2):275-284.
9. Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J. Neurosci. 1983, 3(8):1607-1619.
10. Curet O., de Montigny C. Electrophysiological characterization of adrenoceptors in the rat dorsal hippocampus. II. Receptors mediating the effect of synaptically released norepinephrine. Brain Res. 1988, 475(1):47-57.
11. Dremencov E., El Mansari M., Blier P. Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol. Psychiatry 2007, 61(5):671-678.
12. El Mansari M., Lecours M., Blier P. Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology 2015, 10.1007/s00213-015-3870-9 (in press).
13. Floresco S.B., Todd C.L., Grace A.A. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J. Neurosci. 2001, 21:4915-4922.
14. Frånberg O., Marcus M.M., Ivanov V., Schilström B., Shahid M., Svensson T.H. Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology 2009, 204(2):251-264.
15. Frånberg O., Marcus M.M., Svensson T.H. Involvement of 5-HT2A receptor and α2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow. Synapse (New York, N.Y.) 2012, 66(7):650-660.
16. Frånberg O., Wiker C., Marcus M.M., Konradsson A., Jardemark K., Schilström B., Svensson T.H. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 2008, 196(3):417-429.
17. Gao J., Li M. Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism. Behav. Brain Res. 2013, 257:286-294.
18. Ghanbari R., El Mansari M., Shahid M., Blier P. Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain. Eur. Neuropsychopharmacol. 2009, 19(3):177-187.
19. Grace a.a., Bunney B.S., Moore H., Todd C.L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 1997, 20(1):31-37.
20. Grace A.A., Bunney B.S. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons - 1. Identification and characterization. Neuroscience 1983, 10:301-315.
21. Grace A.A., Bunney B.S. The control of firing pattern in nigral dopamine neurons: burst firing. J. Neurosci.: Off. J. Soc. Neurosci. 1984, 4(11):2877-2890.
22. Haddjeri N., Blier P., de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J. Pharmacol. Exp. Ther. 1996, 277(2):861-871.
23. Haddjeri N., Blier P., de Montigny C. Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J. Affect. Disord. 1998, 51(3):255-266.
24. Haddjeri N., Blier P., de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J. Neurosci.: Off. J. Soc. Neurosci. 1998, 18(23):10150-10156.
25. Jones-Humble S.A., Durcan M.J., Lyerly D., Norton R.M., Tang F.L., Russell A.V., Cox R.F. Preclinical neurochemical and electrophysiological profile of 1192U90, a potential antipsychotic. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 1996, 15(3):217-230.
26. Kane J.M., Cohen M., Zhao J., Alphs L., Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J. Clin. Psychopharmacol. 2010, 30(2):106-115.
27. Kinon B.J., Basson B.R., Gilmore J.A., Tollefson G.D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry 2001, 62(2):92-100.
28. Marston H.M., Martin F.D., Papp M., Gold L., Wong E.H., Shahid M. Attenuation of chronic mild stress-induced "anhedonia" by asenapine is not associated with a "hedonic" profile in intracranial self-stimulation. J. Psychopharmacol. (Oxf., Engl.) 2011, 25(10):1388-1398.
29. Marston H.M., Young J.W., Martin F.D.C., Serpa K.A., Moore C.L., Wong E.H.F., Shahid M. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology 2009, 206(4):699-714.
30. McIntyre R.S., Tohen M., Berk M., Zhao J., Weiller E. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. J. Affect. Disord. 2013, 150(2):378-383.
31. McLean S.L., Neill J.C., Idris N.F., Marston H.M., Wong E.H.F., Shahid M. Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behav. Brain Res. 2010, 214(2):240-247.
32. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2003, 27(7):1159-1172.
33. Oosterhof, N.N., Oosterhof, C.A., 2013. BurstiDAtor: a lightweight discharge analysis program for neural extracellular single unit recordings. Available from: . http://www.github.com/nno/burstiDAtor.
34. Piñeyro G., Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev. 1999, 51(3):533-591.
35. Piñeyro G., Blier P., Dennis T., de Montigny C. Desensitization of the neuronal 5-HT carrier following its long-term blockade. J. Neurosci.: Off. J. Soc. Neurosci. 1994, 14(5 Pt 2):3036-3047.
36. Potkin S.G., Cohen M., Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J. Clin. Psychiatry 2007, 68(10):1492-1500.
37. Ranck J.B. Studies on single neurons in dorsal hippocampal formation and septum in unrestrained rats. I. Behavioral correlates and firing repertoires. Exp. Neurol. 1973, 41(2):461-531.
38. Schoemaker J., Stet L., Vrijland P., Naber D., Panagides J., Emsley R. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry 2012, 45(5):196-203.
39. Shahid M., Walker G.B., Zorn S.H., Wong E.H.F. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. (Oxf., Engl.) 2009, 23(1):65-73.
40. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur. J. Pharmacol. 1995, 281(3):289-294.
41. Sorensen S.M., Kehne J.H., Fadayel G.M., Humphreys T.M., Ketteler H.J., Sullivan C.K., Schmidt C.J. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 1993, 266(2):684-691.
42. Stockton M.E., Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996, 14(2):97-105.
43. Szabo S.T., Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res. 2001, 922(1):9-20.
44. Tarazi F.I., Stahl S.M. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin. Pharmacother. 2012, 13(13):1911-1922.
45. Valenti O., Grace A.A. Antipsychotic drug-induced increases in ventral tegmental area dopamine neuron population activity via activation of the nucleus accumbens-ventral pallidum pathway. Int. J. Neuropsychopharmacol. 2010, 13:845-860.
46. Vandermaelen C.P., Aghajanian G.K. Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res. 1983, 289:109-119.
47. Vogelsang G.D., Piercey M.F. The supersensitivity of dopaminergic neurons to apomorphine in rats following chronic haloperidol. Eur. J. Pharmacol. 1985, 110:267-269.
48. Westerink B.H.C., De Boer P., De Vries J.B., Kruse C.G., Long S.K. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur. J. Pharmacol. 1998, 361:27-33.